Baiyunshan (00874) has announced that its subsidiary, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration. The approval is for adding a new indication for Xuhanting Granules. Xuhanting Granules are known for their effects in replenishing qi and nourishing yin, as well as consolidating the exterior and stopping sweating. They are currently indicated for spontaneous sweating and night sweats due to qi and yin deficiency, including cases in children. As an already-marketed traditional Chinese medicine compound preparation, this application seeks approval to conduct clinical trials for its use in treating recurrent respiratory infections in children.